Serum Concentrations of VEGF and TGF‐β1 During Exclusive Enteral Nutrition in IBD
- 1 August 2011
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 53 (2), 150-155
- https://doi.org/10.1097/mpg.0b013e3182144c74
Abstract
Exclusive enteral nutrition (EEN) is an effective method of treatment in achieving remission in inflammatory bowel disease (IBD); however, its mechanism of action is still poorly understood. The objective of our study was to assess the influence of EEN on serum vascular endothelial growth factor (VEGF) and transforming growth factor-beta 1 (TGF-β1) in children and adolescents with IBD. Thirty-nine children and adolescents with IBD (24 with Crohn disease [CD] and 15 with ulcerative colitis [UC]) and 25 healthy controls were enrolled in the study. VEGF and TGF-β1 were assessed at the baseline and after 2 and 4 weeks of EEN in CD and UC groups and once in controls using enzyme-linked immunosorbent assay immunoassays. At the baseline, we found increased serum VEGF in the CD versus UC group and controls (P < 0.05) and serum TGF-β1 in the UC versus CD group and controls (P < 0.05). During EEN, VEGF decreased in the UC and CD groups, whereas TGF-β1 increased in the CD group and decreased in the UC group. The CD group achieved disease remission faster than the UC group, and the weight gain of patients with CD during EEN was higher compared with patients with UC. Additionally, TGF-β1 concentration correlated with protein and energies daily intake in the CD group (R = 0.95; P < 0.05). Different effectiveness of EEN in achieving remission in CD and UC may result from a modification of growth factor production. EEN stimulated TGF-β1 production in CD but not in UC, which possibly resulted in higher effectiveness of EEN in this group of patients.Keywords
This publication has 38 references indexed in Scilit:
- Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid‐dependent casesJournal of Gastroenterology and Hepatology, 2010
- Antibiotics and probiotics in inflammatory bowel disease: why, when, and howCurrent Opinion in Gastroenterology, 2009
- Transforming growth factor‐beta 1 (TGF‐β1) induces angiogenesis through vascular endothelial growth factor (VEGF)‐mediated apoptosisJournal of Cellular Physiology, 2009
- Crohn's disease: current treatment optionsArchives of Disease in Childhood, 2008
- Nutritional concerns in pediatric inflammatory bowel disease patientsMolecular Nutrition & Food Research, 2008
- A Meta-Analysis of Antibiotic Therapy for Active Ulcerative ColitisDigestive Diseases and Sciences, 2007
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatroy bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 2000
- Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1998
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992